Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neoplasms 2Uterine Cervical Neoplasms 1Sarcoma, Ewing 1Neuroectodermal Tumors, Primitive 1Lymphoma 1Endometrial Neoplasms 1

Interventions

Irinotecan 6Temozolomide 5Cyclophosphamide 5Vincristine 4Magnetic Resonance Spectroscopy 4Doxorubicin 4palbociclib 3X-Rays 3Phantoms, Imaging 3Gemcitabine 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2olaparib 2ivosidenib 2ganitumab 2eribulin 2cixutumumab 2cabozantinib 2abemaciclib 2Vemurafenib 2Specimen Handling 2Radiotherapy, Image-Guided 2Radiosurgery 2Peripheral Blood Stem Cell Transplantation 2Nuclear Medicine Department, Hospital 2Nivolumab 2LY3023414 2FANG vaccine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Sarcoma, Ewing × PM 00104 × Clear all
NCT01222767 2021-10-29

Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy

PharmaMar

Phase 2 Completed
17 enrolled 20 charts
Sarcoma

Sarcoma, Ewing, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon ⚡